You can buy or sell UroGen Pharma and other stocks, options, ETFs, and crypto commission-free!
UroGen Pharma Ltd. Ordinary Shares, also called UroGen Pharma, is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Read More Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in Ra'anana, Israel.
New York, New York
52 Week High
52 Week Low
Simply Wall StMar 8
Imagine Owning UroGen Pharma (NASDAQ:URGN) And Wondering If The 37% Share Price Slide Is Justified
Investors can approximate the average market return by buying an index fund. But if you buy individual stocks, you can do both better or worse than that. For example, the UroGen Pharma Ltd. (NASDAQ:URGN) share price is down 37% in the last year. That falls noticeably short of the market return of around 0.9%. Because UroGen Pharma hasn’t been listed for many years, the market is still learning about how the business performs. Furthermore, it’s down 21% in about a quarter. That’s not much fun for holders. We...
Stock Price, News, & Analysis for Urogen Pharma
Headlines about URGN stock have trended somewhat positive on Wednesday, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Urogen Pharma earned a coverage optimism score of 1.9 on InfoTrie's scale. They also assigned press coverage about the compan...
UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results
NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced financial results for the fourth quarter and full year ended December 31, 2018 and provided an overview of the Company’s recent developments. “Our clinical and corporate execution in 2018 places UroGen in a position of strength as we prepare to potentially deliver UGN-101 as the first approved therapy for patients with low-grad...
Expected May 14, Pre-Market